Overview
CARL market data
Price History
CARL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.17 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -57.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.50 – $17.19 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $382M · P/B 3.32 · P/S 6.77.
Company News
Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20Benzinga · Aug 6, 2026, 3:53 PM
Carlsmed Raises FY2026 Sales Guidance from $72.000M-$77.000M to $74.000M-$78.000M vs $74.830M EstBenzinga · Aug 5, 2026, 8:03 PM
Carlsmed Q2 EPS $(0.39) Beats $(0.41) Estimate, Sales $18.940M Beat $17.948M EstimateBenzinga · Aug 5, 2026, 8:02 PM
Shares of medical device companies are trading higher amid sympathy with Abbott Laboratories after that company reported better-than-expected Q2 financial results and raised its FY adjusted EPS guidance with its midpoint above estimates.Benzinga · Jul 16, 2026, 4:35 PM
Needham Initiates Coverage On Carlsmed with Buy Rating, Announces Price Target of $17Benzinga · Jul 1, 2026, 12:05 PM